Rapid Infusion of Immune Globulin Intravenous (Human) In Primary Immunodeficiency Patients
Status:
Completed
Trial end date:
2004-03-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to determine if the safety and tolerability of Immune Globulin
Intravenous (Human), 10% caprylate/chromatography (IGIV-C)purified is similar when infused at
two different infusion rates. The primary objective is to compare the incidence and severity
of all infusion related adverse events when IGIV-C, 10% is administered at a rate of 0.14
mL/kg/min compared to a rate of 0.08 mL/kg/min after a single daily infusion.
Phase:
Phase 3
Details
Lead Sponsor:
Grifols Therapeutics Inc. Grifols Therapeutics LLC
Treatments:
Antibodies gamma-Globulins Immunoglobulin G Immunoglobulins Immunoglobulins, Intravenous Rho(D) Immune Globulin